Meeting
2021 ASCO Annual Meeting
Phase II study of the anti-TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).
Authors
Peter Grell
Masaryk Memorial Cancer Institute, Brno, Czech Republic
Peter Grell , Chia-Chi Lin , Michele Milella , Cheng Ean Chee , Shivan Sivakumar , Katriina Johanna Peltola , Geraldine Bostel , Dragana Jankovic , Maria-Athina Altzerinakou , Claire Fabre , Armando Santoro
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
NCT04390763
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS4173)
DOI
10.1200/JCO.2021.39.15_suppl.TPS4173
Abstract #
TPS4173
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase II study (daNIS-1) of the anti–TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).
First Author: Li-Yuan Bai
Poster
2022 ASCO Annual Meeting
Phase II study (daNIS-1) of the anti-TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).
First Author: Li-Yuan Bai
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase 1b study evaluating IL-1β and PD-1 targeting with chemotherapy in metastatic pancreatic cancer (PanCAN-SR1).
First Author: Paul Eliezer Oberstein
Poster
2017 ASCO Annual Meeting
The CCTG PA.7 trial: A randomized phase II study of gemcitabine and nab-paclitaxel vs. gemcitabine, nab-paclitaxel, durvalumab, and tremelimumab as 1st line therapy in metastatic pancreatic ductal adenocarcinoma (PDAC).
First Author: Daniel John Renouf